Literature DB >> 1495016

2-Substituted 1-azabicycloalkanes, a new class of non-opiate antinociceptive agents.

J R Carson1, R J Carmosin, J L Vaught, J F Gardocki, M J Costanzo, R B Raffa, H R Almond.   

Abstract

2-Substituted 1-azabicycloalkanes (3- and 5-aryloctahydroindolizines 2 and 11, 3-cyclohexyloctahydroindolizine 12, 4-aryloctahydroquinolizines 13, and 3-arylhexahydropyrrolizines 14) constitute a new class of non-opiate antinociceptive agents. These compounds demonstrated activity in the mouse abdominal constriction test and many were active in the mouse tail-flick test. trans-3-(2-Bromophenyl)octahydroindolizine (2a) did not bind to the opiate receptor nor did it affect arachidonate metabolism. 3-Aryloctahydroindolizines were prepared by catalytic hydrogenation of 1-aryl-3-(2-pyridinyl)-2-propen-1-ones. The X-ray crystal structure of (-)-2a was determined and absolute stereochemistry assigned as 3-R,8a-R.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1495016     DOI: 10.1021/jm00093a019

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Redox cycloisomerization approach to 1,2-dihydropyridines.

Authors:  Barry M Trost; Berenger Biannic
Journal:  Org Lett       Date:  2015-03-11       Impact factor: 6.005

2.  Catalytic Asymmetric Synthesis of Chiral γ-Amino Ketones via Umpolung Reactions of Imines.

Authors:  Lin Hu; Yongwei Wu; Zhe Li; Li Deng
Journal:  J Am Chem Soc       Date:  2016-11-30       Impact factor: 15.419

Review 3.  Enzymatic Kinetic Resolution of 2-Piperidineethanol for the Enantioselective Targeted and Diversity Oriented Synthesis.

Authors:  Dario Perdicchia; Michael S Christodoulou; Gaia Fumagalli; Francesco Calogero; Cristina Marucci; Daniele Passarella
Journal:  Int J Mol Sci       Date:  2015-12-24       Impact factor: 5.923

4.  Unexpected cyclization of ortho-nitrochalcones into 2-alkylideneindolin-3-ones.

Authors:  Nicolai A Aksenov; Dmitrii A Aksenov; Nikolai A Arutiunov; Daria S Aksenova; Alexander V Aksenov; Michael Rubin
Journal:  RSC Adv       Date:  2020-05-14       Impact factor: 3.361

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.